Safety Profile of CAR-T Cell JCAR017 in R/R Aggressive B-NHL patients

David Maloney

David Maloney, BSc, MD, PhD, from Fred Hutchinson Cancer Research Center, Seattle, WA, describes his poster on the safety profile of CAR-T cell JCAR017 in patients with relapsed/refractory aggressive B-NHL patients. He describes how JCAR017 differs from the other CAR-T cell products that exist and answers the question, ‘is there potential for outpatient administration?’ Dr Maloney feels the results presented at ASH 2017 in Atlanta, GA, where this interview was recorded, are very encouraging.

Share this video